Consino Bio: Reorganizing the new crown vaccine was approved by the army for special needs medicines

the morning of June 29, Consino Bio-B, 06185.HK announced that the recombinant new coronavirus vaccine (adenovirus vector) had received
special needs drug approvals.
announced that the recombined new coronavirus vaccine (Ad5-nCoV), developed jointly with the Institute of Bioengineering of the Military
Military Medical Research Institute, was approved by
Ad5-nCoV Phase I and Phase II clinical trials in China on June 25, 2020 and was completed on June 11, 2020. Clinical trial data have shown good safety and high levels of body fluid immunity and cellular immune response, Concino said. The results of the overall trial show that Ad5-nCoV has the potential to prevent diseases caused by SARS-CoV-2.
the announcement mentioned that, in accordance with the relevant provisions of the Chinese People's Liberation Army's Measures for the Implementation of the Drug Administration Law of the People's Republic of China, Ad5-nCoV is limited to the internal use of
at this stage and may not expand the scope of vaccination without the approval of the ministry of post-
protection.
Concino also warns that there is no guarantee that we will eventually succeed in commercializing Ad5-nCoV.
the Ad5-nCoV vaccine was developed by a team of
from the Institute of Bioengineering at the
Military Medical Research Institute. The vaccine is a replication defect Ad5 vector vaccine that expresses SARS-CoV-2 prickly glycoprotein (S protein). The vaccine uses a detoxifying common cold virus (adenovirus, which is susceptible to human cells but does not cause disease) to transmit genetic material encoded to the cells of the SARS-CoV-2 prickly (S) protein. These cells then produce the S protein, which reaches the lymph nodes, and the immune system produces antibodies that recognize the S protein and fight off the coronavirus.
Earlier, on the evening of May 22, The Lancet, a leading medical journal, published a paper entitled "Safety, toerability and immunogenicity of the recombinative adenovirus type 5 vector COVID-19 vaccine: dose increment, open labeling, non-randomized, first human trials". Chen Wei and other researchers reported phase 1 clinical data on the Ad5 vector COVID-19 vaccine used in healthy adults in China within 28 days of vaccination, initially assessing the vaccine's safety, toerability and immunogenicity.
results are an important milestone, " Chen Wei, an official at the time, said at the time. Trials have shown that a single vaccination to replicate the defective human adenovirus type 5 (Ad5) vector new coronary vaccine can induce the production of virus-specific antibodies and T-cell response within 14 days, making it a potential candidate for further research. Chen
said, "We should read these results carefully." The challenge of developing a COVID-19 vaccine is unprecedented, and the ability to induce an immune response does not necessarily mean that the vaccine fully protects humans from SARS-CoV-2. These results offer a positive prospect for the development of the new crown vaccine, but we still have a lot of work to do before the vaccine is available.
Consino Bio was registered in Tianjin Binhai New Area in 2009 and specializes in the development, production and commercialization of high-quality human vaccines, establishing a research and development pipeline for 16 innovative vaccine products in 13 disease areas, covering the prevention of a range of diseases such as new coronavirus pneumonia, Ebola virus disease, tuberculosis, meningitis, white-cracking, shingles and so on. In March 2019, Concino Bio was listed on the H-shares of the main board of the
Stock Exchange, and in January 2020, the company formally submitted its application for listing and acceptance of the board, with a proposal to raise funds for the expansion of new vaccine production capacity and the development of new vaccine products.